{"id":6441,"date":"2022-05-24T12:20:00","date_gmt":"2022-05-24T12:20:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/"},"modified":"2022-05-24T12:20:00","modified_gmt":"2022-05-24T12:20:00","slug":"nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/","title":{"rendered":"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att bolaget har beviljats medel inom ramen f\u00f6r VINNOVA-projektet \u201dVerifiering i Testa Center, del III\u201d till ett belopp p\u00e5 maximalt 290 000 kronor. Medlen kommer anv\u00e4ndas f\u00f6r ett internt forskningsprojekt i Nanexa med m\u00e5let att bel\u00e4gga monoklonala antikroppar (mAbs) med PharmaShell\u00ae.<\/strong><\/p>\n<\/div>\n

\n

Projektet ben\u00e4mns: \u201cA proof-of-concept study of applying prolonged-release coatings onto monoclonal antibodies using the PharmaShell\u00ae technology\u201d.<\/p>\n

\u201dVi ser ett \u00f6kat intresse f\u00f6r PharmaShell bland de riktigt stora l\u00e4kemedelsbolagen, bland annat f\u00f6r applikationer med biologiska l\u00e4kemedel s\u00e5 som peptider, proteiner, polysackarider och inte minst mAbs. Det \u00e4r d\u00e4rf\u00f6r mycket gl\u00e4djande att vi nu kan genomf\u00f6ra egna studier med mAbs och visa f\u00f6rdelarna med PharmaShell inom detta expansiva och mycket intressanta omr\u00e5de.\u201d, s\u00e4ger Nanexas vd David Westberg <\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar parenterala l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n\n

Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att bolaget har beviljats medel inom ramen f\u00f6r VINNOVA-projektet \u201dVerifiering i Testa Center, del III\u201d till ett belopp p\u00e5 maximalt 290 000 kronor. Medlen kommer anv\u00e4ndas f\u00f6r ett internt forskningsprojekt i Nanexa med m\u00e5let att bel\u00e4gga monoklonala antikroppar (mAbs) med PharmaShell\u00ae.<\/p>\n","protected":false},"template":"","class_list":["post-6441","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att bolaget har beviljats medel inom ramen f\u00f6r VINNOVA-projektet \u201dVerifiering i Testa Center, del III\u201d till ett belopp p\u00e5 maximalt 290 000 kronor. Medlen kommer anv\u00e4ndas f\u00f6r ett internt forskningsprojekt i Nanexa med m\u00e5let att bel\u00e4gga monoklonala antikroppar (mAbs) med PharmaShell\u00ae.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\\\/\",\"name\":\"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-05-24T12:20:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar - Nanexa AB","og_description":"Nanexa AB meddelar idag att bolaget har beviljats medel inom ramen f\u00f6r VINNOVA-projektet \u201dVerifiering i Testa Center, del III\u201d till ett belopp p\u00e5 maximalt 290 000 kronor. Medlen kommer anv\u00e4ndas f\u00f6r ett internt forskningsprojekt i Nanexa med m\u00e5let att bel\u00e4gga monoklonala antikroppar (mAbs) med PharmaShell\u00ae.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/","name":"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-05-24T12:20:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-beviljas-bidrag-fran-vinnova-for-studie-med-monoklonala-antikroppar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa beviljas bidrag fr\u00e5n VINNOVA f\u00f6r studie med monoklonala antikroppar"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}